Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Texas Biomedical Research Institute has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, BARRON, SEAN C, who is the busiest examiner with 1 pending case. The prosecution is occurring within 1 distinct art unit, providing a single focus for the institute's current patent activity. This concentration allows for a direct and singular focus on the specific requirements of the assigned examiner.
The presence of only 1 pending office action means that the institute's immediate prosecution risk is limited to a single case. Because there is only 1 distinct examiner and 1 distinct art unit involved, the applicant can dedicate resources to understanding the specific prior art preferences of BARRON, SEAN C. This singular focus within the Biotechnology & Pharmaceuticals technology area simplifies the administrative burden compared to larger portfolios. Practitioners can tailor their arguments specifically to the standards of the 1 distinct art unit identified in the data.
With 1 pending office action, the institute does not currently face the challenge of coordinating responses across multiple examiners or technical groups. The busiest examiner, BARRON, SEAN C, holds the entirety of the institute's pending workload. This 1 pending office action serves as the primary indicator of the institute's current engagement with the USPTO. The lack of additional pending actions suggests a highly targeted approach to its biotechnology filings at this time.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BARRON, SEAN C | 1 | 52.7% | +30.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18928461 | CELL CULTURE MEDIA AND METHODS FOR GENERATING HUMAN ALVEOLAR MACROPHAGE-LIKE CELLS | BARRON, SEAN C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18928461 | CELL CULTURE MEDIA AND METHODS FOR GENERATING HUMAN ALVEOLAR MACROPHAGE-LIKE CELLS | BARRON, SEAN C | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18928461 | CELL CULTURE MEDIA AND METHODS FOR GENERATING HUMAN ALVEOLAR MACROPHAGE-LIKE CELLS | BARRON, SEAN C | 1653 | §102§103§112 | Non-Final OA | — | Pending | Oct 28, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTexas Biomedical Research Institute has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sean C Barron has the most, with 1 of Texas Biomedical Research Institute's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
